People vaccinated outside the United States



People who were vaccinated outside the United States with an FDA-authorized COVID-19 vaccine and have received all the recommended doses do not need any additional doses. People who received the first dose of an FDA-authorized COVID-19 vaccine that requires two doses do not need to restart the vaccine series in the United States but should receive the second dose as close to the recommended time as possible.


Some people may have received a COVID-19 vaccine that is not currently authorized in the United States. No data are available on the safety or efficacy of receiving a COVID-19 vaccine currently authorized in the United States after receipt of a non-FDA-authorized COVID-19 vaccine. However, in some circumstances people who received a COVID-19 vaccine not currently authorized in the United States may be offered revaccination with an FDA-authorized vaccine:

  • COVID-19 vaccines not authorized by FDA but listed for emergency use by the World Health Organization (WHO)2

  • People who have received all recommended doses of a COVID-19 vaccine that has been listed for emergency use by WHO do not need any additional doses with an FDA-authorized COVID-19 vaccine.

  • People who have not received all the recommended doses of a COVID-19 vaccine listed for emergency use by WHO may be offered a complete FDA-authorized COVID-19 vaccine series.

  • COVID-19 vaccines neither authorized by FDA nor listed for emergency use by WHO

  • People who received all or some of the recommended doses of a COVID-19 vaccine that is neither authorized by FDA nor listed for emergency use by WHO may be offered a complete FDA-authorized COVID-19 vaccine series.

The minimum interval between the last dose of a non-FDA authorized vaccine or a WHO-listed vaccine and an FDA-authorized COVID-19 vaccine is 28 days. Only people who have received all recommended doses of an FDA-authorized or WHO-listed COVID-19 vaccine are considered fully vaccinated for the purpose of public health guidance.


SOURCE:

4 views0 comments